In 2011 was created SPARK Impact, which is appeared as Corporate Investor.
Among the most popular portfolio startups of the fund, we may highlight Ai2 UK, Cytox. Among the most successful fund investment fields, there are Medical Device, Genetics. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. The fund has exact preference in some founders of portfolio startups.
Deals in the range of 1 - 5 millions dollars are the general things for fund. The important activity for fund was in 2013. The fund is generally included in less than 2 deals every year.
The usual cause for the fund is to invest in rounds with 3 partakers. Despite the SPARK Impact, startups are often financed by Qi3 Ventures, Masa Life Science Fund, MTI. The meaningful sponsors for the fund in investment in the same round are The North West Fund, MTI, Wren Capital. In the next rounds fund is usually obtained by Innovate UK, Wren Capital, Walking Ventures.
Related Funds
| Fund Name | Location |
| Alpha Square Group | New York, New York, United States |
| Amesto Solutions | Norway, Oslo |
| Arts Alliance | England, London, United Kingdom |
| Be Curious Partners | Atlanta, Georgia, United States |
| CSK Venture Capital | Japan, Tokyo |
| Davis Shapiro Lewit Grabel Leven Granderson & Blake | New York, New York, United States |
| Feiniu | China, Shanghai |
| i2E | Oklahoma, Oklahoma City, United States |
| Incite Media Labs | New York, New York, United States |
| Meraas | Dubai, United Arab Emirates |
| OCS Group | Crawley, United Kingdom, West Sussex |
| Parthenon Capital Partners | Boston, Massachusetts, United States |
| Schottenstein Stores | Columbus, Ohio, United States |
| Techinvest | Austria, Vienna |
| Ulster Bank Ireland | County Dublin, Dublin, Ireland |
| Wells Fargo Startup Accelerator | California, San Francisco, United States |
| Xmark Asset Management | New York, New York, United States |
| Zhixin Zede Touzi | - |
| Zurich Insurance Group | Switzerland, Zürich, Zurich |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Diagnostic Healthcare | $1M | 01 Mar 2013 | England | ||
Cytox | $4M | 30 Jan 2013 | England | ||
Renephra | 01 Jan 2013 | England |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Diagnostic Healthcare | $1M | 01 Mar 2013 | England | ||
Cytox | $4M | 30 Jan 2013 | England | ||
Renephra | 01 Jan 2013 | England |
